概述
-
货号
DHD10801
-
描述
Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.
-
表达系统
Mammalian Cells -
种属反应性
Human -
宿主
Chimeric -
同种型
IgG1-kappa -
克隆类型
Monoclonal -
靶标
CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4 -
浓度
1 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>95% as determined by SDS-PAGE. -
纯化方式
Protein A/G purified from cell culture supernatant. -
Accession号
P15391 -
克隆号
Coltuximab
-
应用
Research Grade Biosimilar -
状态
Liquid -
保存溶液
0.01M PBS, pH 7.4. -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. -
别名
SAR3419, CAS: 1269764-99-9
图片
参考文献
评价
